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Abstract 
Background: Acinetobacter has gained importance as a multi-drug resistant and hence a difficult to treat pathogen. 
This study was done to characterize our isolates with respect to drug resistance and presence of beta-lactamases 
which is a major mechanism of resistance and to type using RAPD and MLST so that comparison of our clones can be 
made with the existing international clones.
Methods: 100 isolates recovered from clinical samples from two hospitals in Delhi were tested for their susceptibility 
against major groups of antimicrobials. The resistant isolates were screened and confirmed phenotypically for pres-
ence of ESBL, MBL and AmpC and MBLs also by PCR. The isolates were typed by RAPD and MLST.
Results: Out of the 100 isolates, 91, 78 and 2 % were MDR, XDR and PDR respectively. 97, 100 and 85 were screen 
positive for ESBL, AmpC and MBL respectively. Of these, 38.1 % were confirmed phenotypically to produce ESBL, 99 % 
produced AmpC and 29.4 % produced MBL comprising of GIM, VIM, SIM and IMP. MLST showed known STs 110, 188, 
146, 69, 103, 108 and 194. Eight new STs were encountered. The RAPD showed a high degree of genetic variability 
among the isolates.
Conclusion: Majority of our isolates were MDR, producing one or more types of beta-lactamases. We encountered 
drug resistant international clones by MLST which are found in other continents there by confirming their spread to 
Indian sub continent. No data on ST types of other Indian isolates is available in the MLST database and hence com-
parison is not possible.
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Background
Acinetobacter species, once considered as opportunistic, 
low virulence pathogens have now emerged as impor-
tant nosocomial pathogens due to their increase in anti-
microbial resistance. The resistance is due to various 
mechanisms including production of different types of 
beta-lactamases including oxacillinases. They are respon-
sible for a number of hospital acquired infections. To 
control the spread of Acinetobacter baumannii (A. bau-
mannii) in the hospital, it is necessary to distinguish the 
outbreak strain from epidemiologically unrelated Acine-
tobacter. This requires the comparison of isolates at the 
subspecies level which is done by epidemiological typ-
ing methods. Phenotypic typing systems based on bio-
chemical profiles (biotyping), antibiotic susceptibility 
patterns, serological reactions (serotyping), phage typ-
ing and protein profiles have mostly been replaced by 
molecular typing systems like ribotyping, Pulsed-field 
gel electrophoresis (PFGE), Amplified fragment length 
polymorphisim (AFLP) analysis, Random amplification 
of polymorphic DNA (RAPD) and many more. PFGE is 
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more sensitive in analysis of Acinetobacter epidemiology 
but it is cumbersome as well as expensive, so RAPD is 
preferred. However, reproducibility and inter-laboratory 
exchange of data for global epidemiological analysis have 
been problematic which is solved by MLST by offering 
the possibility to transfer typing data from laboratory to 
laboratory or compare results via the internet [1].
The present study was undertaken to identify and char-
acterize clinical isolates of A. baumannii with reference 
to its antibiotic susceptibility, presence of the different 
types of β-lactamases in the resistant isolates and molec-
ular typing of the isolates using RAPD and MLST and 
compare them with international clones.
Methods
Institutional ethics committee clearance was taken before 
the start of the project. A total of one hundred (100) non 
repetitive isolates of A. baumannii were collected from 
various clinical specimens from patients attending two 
hospitals in New Delhi after taking patient’s consent. 
The species identification of the isolates was done using 
the API 20NE strips (Biomerieux, Cat No. 20 050) and it 
was further confirmed using Amplified ribosomal DNA 
restriction analysis (ARDRA) [2, 3].
Susceptibility of the isolates to various antibiotics was 
tested by using the Kirby Bauer’s Disk diffusion method. 
The antibiotics used included cefoxitin (30 μg), ceftazi-
dime (30 μg), cefotaxime (30 μg), cefpodoxime (30 μg), 
aztreonam (30 μg), cefepime (30 μg), imipenem (10 μg), 
amikacin (30  μg), ciprofloxacin (30  μg), gentamicin 
(10  μg), ampicillin/sulbactam (20/10  μg), piperacillin/
tazobactam (100/10  μg), tigecycline (15  μg) and colis-
tin(10  μg) discs (Becton–Dickinson). The diameters of 
the zones of inhibition were recorded and interpreted as 
sensitive, intermediate sensitive or resistant, according 
to the CLSI guidelines 2013 [4] except colistin and tige-
cycline where in CLSI guidelines for Acinetobacter is not 
available. Keeping the breakpoints of ≤2 as sensitive and 
≥4 as resistant [5] the zone sizes of colistin in disk dif-
fusion test was taken as ≥11 as susceptible and ≤10 as 
resistant [6, authors unpublished data]. The interpreta-
tion for tigecycline was ≥16  mm as sensitive and ≤12 
as resistant according to Jones et  al. [7]. A. baumannii 
isolates were labelled as Multi-drug resistant (MDR) if 
the isolate was resistant to at least three classes of anti-
microbial agents—all Penicillins and Cephalosporins 
(including inhibitor combinations), Fluroquinolones, and 
Aminoglycosides, Extensive drug resistant (XDR) when 
they were MDR and also resistant to Carbapenems and 
finally, Pan-drug resistant (PDR), those that are XDR and 
also resistant to polymyxins and tigecycline [8].
The isolates were screened for ESBL production 
by checking their susceptibility against ceftazidime, 
cefotaxime, cefpodoxime and aztreonam (each disk of 
30  μg) and the screen positive isolates were confirmed 
phenotypically by the Modified combined disc test in 
which AmpC inhibitory substances, like cloxacillin 
(200  μg/ml) is added into the Mueller–Hinton Agar as 
the coexistence of AmpC β-lactamases along with ESBL 
have been shown to mask the production of ESBL. If 
the zone of inhibition around cefotaxime-clavulanate is 
larger than the zone around the cefotaxime disc then the 
isolate is ESBL positive [9].
Isolates resistant to imipenem and ceftazidime were 
further confirmed for MBL production by Combined disc 
test. An organism was considered to be MBL positive if 
there was an increase of ≥7 mm in the zone of inhibition 
around the imipenem + EDTA disc as compared to imi-
penem disc alone [10]. They were further confirmed for 
the presence of MBL genes, VIM, IMP, GIM, SPM and 
SIM, using multiplex PCR [11].
Similarly, isolates resistant to cefoxitin were confirmed 
phenotypically for the presence of AmpC β-lactamase 
by the AmpC disc test. Briefly, a lawn culture of cefoxi-
tin sensitive E.coli (ATCC 25922) was prepared on Mul-
ler Hinton Agar plate and a cefoxitin disk (30  μg) was 
placed on it. A sterile plain disk was placed next (almost 
touching) to the cefoxitin disk, moistened with 20 μl of 
sterile saline and inoculated with several colonies of the 
test organism. A flattening or indentation of the cefoxitin 
inhibition zone in the vicinity of the inoculated disc was 
considered as a positive test [12].
Typing of the isolates was done using RAPD and MLST 
methods.
RAPD was performed by the method described by 
Karthika et  al. 2009 [13]. Amplification was carried out 
in a final volume of 10  μl of the amplification mixture 
containing 1U of Taq Polymerase, 1X of PCR buffer 
(with MgCl2), 50  pmol of primer, 50  μM of deoxynu-
cleotide triphosphate (dNTP) and 1 μl of DNA template. 
AP6 CCCGTCAGCA was used as a primer. 35 cycles of 
94  °C for 30  s, 45  °C for 45  s, 72  °C for 2  min followed 
by a final extension 72  °C for 5 min. The PCR products 
were resolved using 1.2  % agarose gel. A low molecular 
weight DNA ladder (New England Biolabs Inc., Category 
no. N3233S) was used. The image of the gel was captured 
and the banding pattern was analyzed using Gelcompar 
II software (Applied-Maths, Kortrijk, Belgium) and the 
dendrogram was generated.
For MLST, seven housekeeping genes were amplified 
using the method described by Bartual et  al., [14] with 
some modifications in the sequence of gyrB and rpoD 
primers as given by Park et  al. [15]. The PCR products 
were resolved by 1 % agarose gel electrophoresis. Ampli-
fied fragments were sequenced by outsourcing to a com-
mercial company. The sequences obtained were trimmed 
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using the Bio Edit Sequence alignment editor software 
(Ibis Biosciences, Carlsbad, CA, USA). The assignment of 
alleles and sequence types was performed by the software 
available in the Department of Zoology, Oxford Univer-
sity website noted above. The sequence types not pre-
sent in the database were submitted to the website and 
assigned new ST types.
Results
Out of the 100 isolates of A. baumannii 14 % were iso-
lated from sputum, 31  % from ET aspirate, 28  % from 
pus, 25  % from wound swab, 1  % from drain fluid and 
1 % from high vaginal swab. A. baumannii was isolated 
from ICU (28  %), followed by burns ward and respira-
tory medicine ward (15  % each), surgery ward (14  %) 
burns ICU (11 %) gynaecology ward (9 %), orthopaedics 
ward (5 %), respiratory medicine OPD (2 %). Respiratory 
samples were from patients suffering from exacerba-
tion of Chronic obstructive pulmonary disease, Asthma, 
Chronic bronchitis and Ventilator associated pneumonia.
The results for detection of A. baumannii by ARDRA 
(using three enzymes) and API 20 NE strips were 
identical.
The antibiotic susceptibility of the isolates is as shown 
in Table  1. High percentage of resistance was seen to 
most antibiotics except colistin and tigecycline.
Out of the 100 isolates, 91  % were MDR, 78  % were 
XDR and 2 % were PDR.
Screening tests showed 97 (97 %), 100 (100 %) and 85 
(85 %) were positive for ESBL, AmpC and MBL respec-
tively. Out of these screen positive isolates, 37 (38.1 %), 
99 (99 %) and 25 (25 %) were confirmed phenotypically 
to produce ESBL, AmpC and MBL respectively. 18 out 
of the 25 isolates that were confirmed phenotypically for 
MBL production, were positive for GIM (n  =  6), VIM 
(n = 9), SIM (n = 2) and IMP (n = 1) by PCR. AmpC was 
seen to be produced by all but one isolate. It existed in 
combination with ESBL in 37 isolates and with MBL in 
25. Interestingly, 7 isolates showed the production of all 
three.
Total of 100 isolates were typed using RAPD. 86 isolates 
were from one hospital and 14 from the other. Figure 1 
shows the dendrogram of the isolates showing percent-
age similarity between them. A high degree of genetic 
variability was observed among the 100 isolates, includ-
ing 53 distinct RAPD patterns with >20  % difference in 
UPGMA generated dice coefficients. 18 of these showed 
100  % similarity. Majority of the isolates in each clonal 
type were restricted to the same hospital. However, few 
clonal types showed isolates from both the hospitals. The 
discriminatory index of 0.984 was found to be good.
MLST was done on 21 isolates representative of dif-
ferent clones as indicated by RAPD. One isolate each of 
STs 110, 103, 108, 194 and 14, two isolates each of ST 146 
and 69 and three isolates of ST 188 were encountered. 
Nine isolates were found to have new ST types and were 
submitted to the PUBMLST site and were assigned the 
types. The new STs assigned were, ST 386 (n = 1), ST 387 
(n = 1), ST 388 (n = 1), ST 389 (n = 1), ST 390 (n = 2) 
and ST 391 (n = 3) (Table 2).
Discussion
The distribution of the isolates among the specimen and 
the wards were similar to a recent study done in North 
India where it was seen that maximum number of Aci-
netobacter were isolated from pus (37.14 %), followed by 
blood (23 %) and urine (13.6 %). The highest percentage 
of isolation was from the ICU (22  %), followed by pae-
diatrics (21 %), neurosurgery (16 %) and general surgery 
ward (13 %) [16].
When compared with other Gram-negative bacilli, 
the outer membrane of A. baumannii is less permeable 
which might be due to the small number and size of por-
ins and thus it is intrinsically less susceptible to antimi-
crobial agents [17].
The resistance of A. baumannii isolates to Cephalo-
sporins was similar to the findings of studies done in 
Saudi Arabia and Nigeria where in the resistance was 
found to range from 70 to 100 % [19] which might be due 
to the extensive use of Cephalosporins in these hospitals.
The resistance to the Aminoglycosides—amikacin 
and gentamicin was similar to the results in two studies 
where it was found to be 78.2–79.5 and 96.2  % respec-
tively [20, 21]. In contrast, a few studies which were car-
ried out in China and Malaysia showed that it was as low 
as 20.5–57.4 and 66.7 % respectively, which might be due 
Table 1 Antibiotic susceptibility pattern of  A. baumannii 
isolates (n = 100)
Antibiotics Resistant (%) Intermediate (%) Susceptible (%)
Ceftazidime 99 (99) 1 (1) 0 (0)
Cefotaxime 100 (100) 0 (0) 0 (0)
Cefpodoxime 100 (100) 0 (0) 0 (0)
Aztreonam 99 (99) 1 (1) 0 (0)
Imipenem 85 (85) 5 (5) 10 (10)
Cefoxitin 100 (100) 0 (0) 0 (0)
Amikacin 97 (97) 0 (0) 3 (3)
Ciprofloxacin 98 (98) 1 (1) 1 (1)
Gentamicin 95 (95) 1 (1) 4 (4)
Piperacillin–tazo-
bactam
85 (85) 8 (8) 7 (7)
Cefepime 100 (100) 0 (0) 0 (0)
Ampicillin–sulbac-
tam
65 (65) 14 (14) 21 (21)
Tigecycline 42 (42) – 58 (58)
Colistin 3 (3) – 97 (97)
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Fig. 1 UPGMA clustering dendrogram indicating percentage similarity between RAPD patterns of A. baumannii isolates from Safdarjung hospital 
and VPCI
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to the controlled use of Aminoglycosides in these hospi-
tals [22, 23].
The resistance to Fluroquinolone, like ciprofloxacin, 
was similar to a study from Egypt which showed the 
resistance to be 85 % [24].
After the development of resistance to Fluoroquonolo-
nes, Carbapenem is usually the drug of choice for infec-
tions caused by Multi-drug resistant A. baumannii but 
unfortunately, Carbapenem-resistant isolates are con-
stantly on the rise. In the present study, the resistance to 
imipenem (85 %) was similar to the findings from other 
parts of the world. [25–27]. In contrast three studies, 
two from India and one from Saudi Arabia, showed the 
resistance to be still as low as 0 and 9 % respectively. This 
might be due to the small number of isolates tested in 
these studies. [28–30].
With the increase in Carbapenem-resistance, tigecy-
cline and colistin have been used for treatment of the 
infections caused by Extensive-drug resistant (XDR) A. 
baumannii.
There is no CLSI guidelines for the disk diffusion cri-
teria for A. baumannii. United States Food and Drug 
Administration breakpoint criteria for tigecycline when 
testing Enterobactericeae (Susceptibility at ≤2  μg/ml, 
intermediate at 4 μg/ml and resistant at ≥8 μg/ml and 
the corresponding disc diffusion diameters as ≥19 and 
≤14  mm for sensitive and resistant strains respectively) 
is being followed by various authors. But it was observed 
by Jones et al., that using these zone sizes many isolates 
were falsely labelled as resistant [7]. She proposed that 
by using the zone diameters as ≥16 mm for sensitive and 
≤12 mm for resistant isolates reduced the error rate to a 
minimum. Thus, using these criteria, in the present study, 
resistance to tigecycline was found to be 42 % which was 
similar to a study done in Taiwan in which it was 45.5 % 
[31]. But, it was very high in comparison to a study by 
Behera et  al. [32] in which, in spite of using the FDA 
breakpoints, the resistance was only 7.6  %. This could 
be due to the fact that the study was conducted in 2007 
when tigecycline was not used as frequently as Carbap-
enems for the treatment of these infections. Resistance to 
tigecycline has also increased in the past few years [33].
In this study, the resistance to colistin was similar to 
that seen in three other studies, one each from India, 
Egypt and Taiwan which showed a resistance of 3.5, 
5 and 10  % respectively [18, 22, 30]. This might be due 
to the fact that colistin is a reserve drug and used only 
for multi-drug resistant cases. However, a recent study 
from the United States showed that 14 out of 28 isolates 
were colistin resistant [34]. This is because of the rise in 
Table 2 Sequence types of Acinetobacter baumannii isolates encountered in the study
S.no. serial number
* New STs found in the study
S. no ST gltA gyrB gdhB recA cpn60 Gpi rpoD Strain
1 386* 31 33 67 40 1 102 7 In-S 58938
2 387* 1 15 4 11 4 140 4 In-S 95167
3 388* 1 15 4 11 4 95 4 In-S 91318
4 389* 1 7 8 11 1 4 14 In-S 93192
5 390* 31 33 67 40 1 58 7 In-S 100924
6 391* 1 15 13 12 4 102 2 In-V 1687/11
7 391* 1 15 13 12 4 102 2 In-V 323/05
8 391* 1 15 13 12 4 102 2 In-V 5930/11
9 390* 31 33 67 40 1 58 7 In-V 5290/10
10 14 1 10 8 6 1 4 14 In-S 84570
11 103 12 17 12 1 29 3 39 In-S 90868
12 69 1 46 3 2 2 58 3 In-S 98632
13 69 1 46 3 2 2 58 3 In-S 101149
14 108 10 12 4 6 4 9 5 In-S 101767
15 194 1 15 4 11 4 58 4 In-S 102704
16 110 1 15 2 28 1 52 32 In-V 5290/08
17 188 31 33 67 40 16 58 7 In-V 7362/07
18 188 31 33 67 40 16 58 7 In-V 3507/06
19 188 31 33 67 40 16 58 7 In-S 88877
20 146 1 15 13 12 4 14 2 In-V 8095/10
21 146 1 15 13 12 4 14 2 In-S 92729
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MDR Acinetobacter where in, colistin is the only choice 
available for the treatment. Hence, resistance to it is also 
emerging. The resistance to antibiotics reflects on the 
policy of antimicrobial usage and the circulation of drug 
resistant clones in different countries.
In the present study it was seen that out of the 100 
isolates, 91 % were MDR, 78 % were XDR and 2 % were 
PDR. Similar findings were seen in another study. [35]. 
However, a study from North India showed lower per-
centage of isolates to be MDR. [20]. This could be due to 
the fact that the study was done in 2007–2008 and usage 
of Carbapenems and hence, resistance to it has increased 
since then.
The resistance to the various antibiotics is commonly 
due to the production of β-lactamases out of which 
the Extended spectrum β-lactamse (ESBL), AmpC 
β-lactamase and the Metallo β-lactamase (MBL) were 
studied here. All these three mechanisms have been 
observed in the present study.
Detection of lower number of MBLs by PCR is due to 
the fact that MBLs are only one of many mechanisms 
for Carbapenem resistance. Oxacillanases are important 
cause of Carbapenem resistance in Acinetobacter. Unfor-
tunately we could not test for it.
In the present study, 99  % of the isolates produced 
AmpC, 37 % in combination with ESBL and 25 % in com-
bination with MBL. Co-production of all the three, ESBL, 
AmpC and MBL were found in 7 % of our isolates. This 
could explain the increased rates of MDR in our study.
RAPD was done to detect clones which could be fur-
ther typed by MLST. In the current study RAPD showed 
a high degree of genetic variability among the 100 iso-
lates, with 53 distinct RAPD patterns out of which 18 
(consisting of 2–5 isolates each) showed 100 % similarity 
between the isolates. The clonal types were not restricted 
to specific wards but were spread all over. They seem to 
be mostly restricted to the same hospital though a few 
were seen in both hospitals. Interestingly, one clonal 
type comprising of 5 isolates isolated from tracheal aspi-
rates of different patients in the ICU of SJH, were Exten-
sive-drug resistant, resistant to tigecycline, sensitive to 
colistin. Another clonal type included 6 isolates from 
different samples and different wards of SJH but all were 
Extensive-drug resistant, sensitive to colistin and all but 
one were sensitive to tigecycline. There were many other 
clonal types but they did not correlate with the antibio-
types. In a study done in India it was seen that the RAPD 
results did not correlate with those of antibiotypes since 
the isolates showed highly divergent resistance profiles. 
Only a few correlations could be made [13].
PUBMLST database has 2738 Acinetobacter bauman-
nii isolates with 920 assigned STs. Analyzing the data 
by eBURST, 78 groups (each having 6 or more loci in 
common) were identified. Out of all the STs identified 
319 were singletons not belonging to any group. Even 
among the 78 groups a founder could only be identi-
fied in very few suggesting high diversity among the 
isolates (http://pubmlst.org/abaumannii/). Few of the 
STs found in the study with clonal complex 92, 104, 109, 
110 and 20 belonged to international clones and are dis-
tributed in different continents of the world suggesting 
their spread to India due to frequent travel between the 
continents. Most of these clones are multidrug resist-
ant and that could explain the increased percentage of 
MDR in our study. So far, there is no published data on 
the sequence types of other Indian isolates. MLST data-
base does not contain ST of Indian isolates. Therefore, 
the prevalence of the ST types in India cannot be com-
mented upon.
In comparison of ST types with the antibiotic resist-
ance pattern it was observed that, ST146 (CC20) clone 
consisting of 2 isolates which were XDR and sensitive 
to both tigecycline and colistin, did not produce ESBL 
or MBL but produced AmpC β-lactamase, were from 
different clinical samples and different wards. CC20 is 
an international clone and is known to produce Oxa 
51- and 68-variants. This could explain the XDR nature 
of our isolates though we did not test for oxacillinases. 
Two other isolates belonged to another clone ST69 
and they were both XDR, resistant to tigecycline and 
sensitive to colistin, producing both ESBL and AmpC 
β-lactamase but they belonged to different wards. 
ST110 clone consisted of two isolates which although 
had different antibiotic susceptibility, they produced 
the same type of β-lactamase. ST188 clone with three 
isolates showed similar antibiotic susceptibility but dif-
fered in the type of β-lactamase produced. The discord-
ance between the ST types and antibiotic resistance 
and/or the β-lactamase types could be due to the fact 
that MLST is based on the house keeping genes but the 
genes responsible for resistance and virulence could be 
located on mobile elements and clustered in genomic 
islands and are not linked to particular sequence types. 
The new STs encountered in our study were mostly sen-
sitive to colistin and resistant to tigecycline. They were 
closely related and were either single locus variants or 
double locus variants of existing clones. For example ST 
390 is a SLV and 386 a DLV of known ST 188. These two 
differed from 188 in that both were resistant to tigecy-
cline. All of these were isolates from respiratory sam-
ples. Similarly ST 387 and 388 were SLV and DLV of ST 
194 respectively. All these isolates were from burns unit 
of the same hospital. Two of the three were resistant 
to tigecycline. These data show that genetic variations 
have occurred locally in the existing clones to give the 
new STs.
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Conclusion
A high percentage of MDR and XDR Acinetobacter 
obtained in the study is due to acquisition of various 
kinds of beta lactamases most of these belonging to 
resistant international clones. Hence, A. baumannii has 
developed into one of the most difficult hospital patho-
gens to control and treat. As of now colistin is the only 
drug of choice due to its low resistance. But keeping in 
mind the nephrotoxicity, patients should be carefully 
treated giving adequate dosage and proper schedul-
ing. Restrained and careful use of antibiotics as well as 
strict infection control policy is crucial for preventing 
the emergence of complete resistance and spread of this 
pathogen. RAPD with a discriminatory index of 0.984 
can be used to type isolates. MLST should be performed 
for epidemiological surveillance so as to learn about the 
variability and prevalence of MDR clones in the world.
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